Tesamorelin 10mg

🧬 Sculptra (Tesamorelin 10mg)

Sculptra (Tesamorelin) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH), studied for its ability to stimulate endogenous growth hormone secretion. It has been investigated for metabolic regulation, body composition improvement, and lipodystrophy management.

📊 Key Findings from Studies

- FDA Approval Context: Tesamorelin is FDA‑approved for the treatment of HIV‑associated lipodystrophy, where it reduces visceral adipose tissue.  

- Growth Hormone Stimulation: Research shows Sculptra (Tesamorelin) increases pulsatile GH release, leading to elevated IGF‑1 levels.  

- Body Composition: Clinical studies demonstrated reductions in abdominal fat and improvements in metabolic markers.  

- Metabolic Benefits: Investigations suggest potential improvements in lipid profiles, insulin sensitivity, and energy balance.  

- Anti‑Aging Research: Tesamorelin has been explored for its role in muscle preservation, recovery, and regenerative pathways, though long‑term safety remains under study.  

⚙️ Mechanism of Action

Sculptra (Tesamorelin) works by:  

- Binding to GHRH receptors in the pituitary gland.  

- Stimulating natural GH release in a physiologic pulsatile manner.  

- Elevating IGF‑1, which drives protein synthesis, muscle growth, and metabolic regulation.  

⚠️ Compliance & Research Use

- Not FDA‑approved for general use; investigational status only outside HIV‑associated lipodystrophy.  

- Labeling must include:  

  - “Not for human consumption”  

  - “Research purposes only”  

Sculptra (Tesamorelin 10mg) is a synthetic peptide analog of GHRH studied for its ability to stimulate natural growth hormone release. Research has shown Sculptra (Tesamorelin) elevates IGF‑1, reduces visceral fat, and supports metabolic regulation. Offered in a 3ml research‑use vial containing 10mg lyophilized powder.

Not for human consumption. Research purposes